In April 2025, DexCom received approval for its G7 15-Day CGM system, a development that was anticipated based on previous management comments. While this approval is not expected to significantly ...

In the first quarter, Dexcom’s G7 system continued its robust momentum. Accelerated conversion of the installed base for G7 manufacturing is driving strong revenue performance and improving ...

Internationally, Dexcom has seen pockets of strength in key markets, such as Japan and France, where recent type 2 diabetes coverage expansions have driven growth. New Product Launch: Dexcom plans to ...

Dexcom reaffirmed its 2025 revenue guidance of ... with evident confidence in key initiatives like the 15-day G7 launch. Revenue growth accelerated to 14% in Q1 2025 from 8% in Q4 2024.

Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on ...

May 27, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) announced today that GlucoGuard has completed the ...

In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

What Makes Stelo – and OTC CGMs – Different Traditional prescription CGMs like the Dexcom G7 are designed for people with diabetes, offering tight integration with insulin pumps, customizable ...

Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.

Gwyneth Paltrow is once again at the center of social media buzz, for what fans believe may be a health-related device ...